Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
452-02-013 / 452-02-013 ISMRM Abstract

Virtual Brain Modeling Reveals Altered Excitatory/Inhibitory Balance and Predicts Symptom Severity in Schizophrenia

Primary: Neuro - Psychiatric Disorders
Secondary: Brain Function and fMRI - Functional Connectivity
452-02-013 · Methodology: Acquisition and Analysis · Tuesday, 12 May, 1:40 PM–3:16 PM · Power Pitch Theatre 2
452-02-013 · Methodology: Acquisition and Analysis · Tuesday, 12 May, 1:40 PM–3:16 PM · Power Pitch Theatre 2
Keywords: Schizophrenia The Virtual Brain Treatment-Resistant Schizophrenia Excitatory-inhibitory balance Symptom severity
Accepted
Matteo Vitacca 1, Doris Pischedda1, Anita Monteverdi2, Giuseppe De Simone3, Mariateresa Ciccarelli3, Giuseppe Pontillo4, Sirio Cocozza4, Andrea De Bartolomeis3, Claudia A Gandini Wheeler-Kingshott, Fulvia Palesi1, Egidio D’Angelo1,2
1Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
2Digital Neuroscience Centre, IRCCS Mondino Foundation, Pavia, Italy
3Section of Psychiatry - Unit of Treatment Resistant Psychosis - Laboratory of Molecular and Translational Psychiatry - Department of Neuroscience, Reproductive and Odontostomatological Sciences, University "Federico II", Naples, Italy
4Department of Advanced Biomedical Sciences, University "Federico II", Naples, Italy
Presenting Author: Matteo Vitacca

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Reh, R. K., Dias, B. G., Nelson, C. A., Kaufer, D., Werker, J. F., Kolb, B., Levine, J. D., & Hensch, T. K. (2020). Critical period regulation across multiple timescales. Proceedings of the National Academy of Sciences of the United States of America, 117(38), 23242–23251. https://doi.org/10.1073/pnas.1820836117 [doi]
2. Blahova, Z., Ikezawa, S., Falkai, P., Krystal, J. H., & Rangan, T. (2024). CONNEX, a Phase III Randomized Trial Program Assessing Efficacy and Safety of Iclepertin in Schizophrenia: Recruitment and Baseline Characteristics. BJPsych Open, 10(S1), S72–S73. https://doi.org/10.1192/bjo.2024.230 [doi]
3. Fleischhacker, W. W., Podhorna, J., Gröschl, M., Hake, S., Zhao, Y., Huang, S., Keefe, R. S. E., Desch, M., Brenner, R., Walling, D. P., Mantero-Atienza, E., Nakagome, K., & Pollentier, S. (2021). Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: A double-blind, randomised, placebo- controlled phase 2 study. The Lancet Psychiatry, 8(3), 191–201. https://doi.org/10.1016/S2215-0366(20)30513-7 [doi]
4. Modinos, G., Allen, P., Grace, A. A., & McGuire, P. (2015). Translating the MAM model of psychosis to humans. Trends in Neurosciences, 38(3), 129–138. https://doi.org/10.1016/j.tins.2014.12.005 [doi]
5. Schobel, S. A., Chaudhury, N. H., Khan, U. A., Paniagua, B., Styner, M. A., Asllani, I., Inbar, B. P., Corcoran, C. M., Lieberman, J. A., Moore, H., & Small, S. A. (2013). Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron, 78(1), 81–93. https://doi.org/10.1016/j.neuron.2013.02.011 [doi]
6. Howes, O. D., & Shatalina, E. (2022). Integrating the Neurodevelopmental and Dopamine Hypotheses of Schizophrenia and the Role of Cortical Excitation-Inhibition Balance. Biological Psychiatry, 92(6), 501–513. https://doi.org/10.1016/j.biopsych.2022.06.017 [doi]
7. Dong, D., Wang, Y., Chang, X., Luo, C., & Yao, D. (2018). Dysfunction of Large-Scale Brain Networks in Schizophrenia: A Meta-analysis of Resting-State Functional Connectivity. Schizophrenia Bulletin, 44(1), 168–181. https://doi.org/10.1093/schbul/sbx034 [doi]
8. King, S., Mothersill, D., Holleran, L., Patlola, S. R., Burke, T., McManus, R., Kenyon, M., McDonald, C., Hallahan, B., Corvin, A., Morris, D. W., Kelly, J. P., McKernan, D. P., & Donohoe, G. (2023). Early life stress, low-grade systemic inflammation and weaker suppression of the default mode network (DMN) during face processing in Schizophrenia. Translational Psychiatry, 13(1), 213. https://doi.org/10.1038/s41398-023-02512-4 [doi]
9. Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W.T., Castle, D. J., Citrome, L., Daskalakis, Z. J., Davidson, M., Drake, R. J., Dursun, S., Ebdrup, B. H., Elkis, H., Falkai, P., … Correll, C. U. (2017). Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 174(3), 216–229. https://doi.org/10.1176/appi.ajp.2016.16050503 [doi]
10. Smith, R. E., Tournier, J.-D., Calamante, F., & Connelly, A. (2012). Anatomically-constrained tractography: Improved diffusion MRI streamlines tractography through effective use of anatomical information. NeuroImage, 62(3), 1924–1938. https://doi.org/10.1016/j.neuroimage.2012.06.005 [doi]
11. Tournier, J.-D., Smith, R., Raffelt, D., Tabbara, R., Dhollander, T., Pietsch, M., Christiaens, D., Jeurissen, B., Yeh, C.-H., & Connelly, A. (2019). MRtrix3: A fast, flexible and open software framework for medical image processing and visuali
12. Deco, G., Ponce-Alvarez, A., Hagmann, P., Romani, G. L., Mantini, D., & Corbetta, M. (2014). How local excitation-inhibition ratio impacts the whole brain dynamics. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 34(23), 7886–7898. https://doi.org/10.1523/JNEUROSCI.5068-13.2014 [doi]
13. Balu, D. T. (2016). Chapter Twelve - The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment. In R. Schwarcz (Ed.), Advances in Pharmacology (Vol. 76, pp. 351–382). Academic Press. https://doi.org/10.1016/bs.apha.2016.01.006 [doi]
14. Coyle, J. T. (2012). NMDA Receptor and Schizophrenia: A Brief History. Schizophrenia Bulletin, 38(5), 920–926. https://doi.org/10.1093/schbul/sbs076 [doi]
15. Emamian, E. S., Karayiorgou, M., & Gogos, J. A. (2004). Decreased Phosphorylation of NMDA Receptor Type 1 at Serine 897 in Brains of Patients with Schizophrenia. Journal of Neuroscience, 24(7), 1561–1564. https://doi.org/10.1523/JNEUROSCI.4650-03.2004 [doi]
16. Ajunwa, C. C., Zhang, J., Collin, G., Keshavan, M. S., Tang, Y., Zhang, T., Li, H., Shenton, M. E., Stone, W. S., Wang, J., Niznikiewicz, M., & Whitfield-Gabrieli, S. (2024). Dissociable Default Mode Network Connectivity Patterns Underlie Distinct Symptoms in Psychosis Risk. bioRxiv: The Preprint Server for Biology, 2024.10.25.620271. https://doi.org/10.1101/2024.10.25.620271 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/452-02-013